EpiCept Corporation recently announced operating and financial results for the year 2010, and provided an update on its key business initiatives.
Browsing: adventrx pharmaceuticals
ADVENTRX Pharmaceuticals, Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary product candidates principally for the treatment of cancer, recently provided an update on its product candidate, ANX-514, its polysorbate 80-free formulation of docetaxel.
The New York Society of Security Analysts, a leading forum for the investment community, recently announced the presenter list for its 14th Annual Biotech and Specialty Pharma Conference.
The San Diego-based company seeks to improve upon existing cancer therapeutics with its reformulations of the chemotherapy drugs Navelbine and Taxotere.